Literature DB >> 7883777

Influence of hexadecylphosphocholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitro.

R Zeisig1, M Rudolf, I Eue, D Arndt.   

Abstract

Hexadecylphosphocholine (HPC) has been investigated intensively for its cancerostatic properties. One explanation for the mechanism of action of HPC assumes that it plays a role in stimulation of the immune system. In particular, its potency to activate macrophages has already been recognised for different lyso- and ether lipids. Important steps in the cascade for developing cytotoxic effects of macrophages on tumor cells are the release of nitric oxide radicals (NO) and/or tumor necrosis factor (TNF). The aim of our study was to examine the role of HPC as primer and/or trigger for macrophage activation to cytotoxicity. In our experiments we used HPC in free (micellar) or liposomal form in different primer/trigger combinations with lipopolysaccharide (LPS). A weak change in morphology was revealed by electron microscopy, if macrophages were harvested from mice previously treated with HPC or HPC multilamellar vesicles. This observation was quantified by the measurement of NO, TNF and cytotoxic activity of the peritoneal macrophages. A specific release of NO was induced by the combination of in vivo treatment with liposomal HPC and subsequent stimulation by LPS in vitro. This process started only after 12 h of in vitro incubation of macrophages with the endotoxin. The release of TNF was dependent of the primer/trigger combination used. A moderate priming effect was obtained with HPC in liposomal form independently of the trigger. On the other hand, liposomes as priming agents were found to induce a dramatic increase in TNF release after in vitro coculture with the trigger LPS. The high release of NO and TNF is accompanied by only a weak increase in tumor cytostasis. The best results were once more found with macrophages primed with liposomal HPC and then triggered with LPS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7883777     DOI: 10.1007/bf01202215

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  31 in total

Review 1.  Induction of tumor cell differentiation by alkylphosphocholines: a new approach for in vitro screening.

Authors:  H R Maurer; P Hilgard
Journal:  Prog Exp Tumor Res       Date:  1992

2.  Abilities of activated macrophages to manifest tumoricidal activity and to generate reactive nitrogen intermediates: a comparative study in vitro and ex vivo.

Authors:  R Keller; R Keist
Journal:  Biochem Biophys Res Commun       Date:  1989-11-15       Impact factor: 3.575

3.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes.

Authors:  T Espevik; J Nissen-Meyer
Journal:  J Immunol Methods       Date:  1986-12-04       Impact factor: 2.303

4.  Gene regulation in macrophage activation: differential regulation of genes encoding for tumor necrosis factor, interleukin-1, JE, and KC by interferon-gamma and lipopolysaccharide.

Authors:  S F Yu; T J Koerner; D O Adams
Journal:  J Leukoc Biol       Date:  1990-11       Impact factor: 4.962

5.  Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon gamma and lipopolysaccharide.

Authors:  C J Lowenstein; E W Alley; P Raval; A M Snowman; S H Snyder; S W Russell; W J Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

6.  Antitumor effects of alkylphosphocholines in different murine tumor models: use of liposomal preparations.

Authors:  R Zeisig; I Fichtner; D Arndt; S Jungmann
Journal:  Anticancer Drugs       Date:  1991-08       Impact factor: 2.248

7.  Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production.

Authors:  A H Ding; C F Nathan; D J Stuehr
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

8.  Synergism between human recombinant monocyte chemotactic and activating factor and lipopolysaccharide for activation of antitumor properties in human blood monocytes.

Authors:  R K Singh; I J Fidler
Journal:  Lymphokine Cytokine Res       Date:  1993-10

9.  Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing. Molecular basis for the synergy between interferon-gamma and lipopolysaccharide.

Authors:  R B Lorsbach; W J Murphy; C J Lowenstein; S H Snyder; S W Russell
Journal:  J Biol Chem       Date:  1993-01-25       Impact factor: 5.157

10.  Phospholipid analogues: side chain- and polar head group-dependent effects on phosphatidylcholine biosynthesis.

Authors:  C C Geilen; A Haase; T Wieder; D Arndt; R Zeisig; W Reutter
Journal:  J Lipid Res       Date:  1994-04       Impact factor: 5.922

View more
  10 in total

1.  Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.

Authors:  Victor B Saraiva; Daniel Gibaldi; José O Previato; Lucia Mendonça-Previato; Marcelo T Bozza; Célio G Freire-De-Lima; Norton Heise
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.

Authors:  P Escobar; V Yardley; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Miltefosine efficiently eliminates Leishmania major amastigotes from infected murine dendritic cells without altering their immune functions.

Authors:  Klaus Griewank; Caroline Gazeau; Andreas Eichhorn; Esther von Stebut
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

4.  Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice.

Authors:  Y Le Fichoux; D Rousseau; B Ferrua; S Ruette; A Lelièvre; D Grousson; J Kubar
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

5.  Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment.

Authors:  H W Murray; A Jungbluth; E Ritter; C Montelibano; M W Marino
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

6.  Alkylphosphocholine-induced production of nitric oxide and tumor necrosis factor alpha by U 937 cells.

Authors:  I Eue; R Zeisig; D Arndt
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

7.  Influence of cancerostatic perifosine on membrane fluidity of liposomes and different cell lines as measured by electron paramagnetic resonance.

Authors:  Rok Podlipec; Tilen Koklic; Janez Strancar; Janez Mravljak; Marjeta Sentjurc
Journal:  Croat Med J       Date:  2012-12       Impact factor: 1.351

8.  Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil.

Authors:  Fabio Dos Santos Nogueira; Valdir Carlos Avino; Fredy Galvis-Ovallos; Vera Lucia Pereira-Chioccola; Marcio Antonio Batistella Moreira; Ana Paula Peres Lopes Romariz; Leticia M Molla; Ingrid Menz
Journal:  Parasit Vectors       Date:  2019-02-08       Impact factor: 3.876

9.  Leishmania major infection in humanized mice induces systemic infection and provokes a nonprotective human immune response.

Authors:  Anja Kathrin Wege; Christian Florian; Wolfgang Ernst; Nicole Zimara; Ulrike Schleicher; Frank Hanses; Maximilian Schmid; Uwe Ritter
Journal:  PLoS Negl Trop Dis       Date:  2012-07-24

10.  Evaluation of the Ability of Miltefosine Associated with Topical GM-CSF in Modulating the Immune Response of Patients with Cutaneous Leishmaniasis.

Authors:  Fábio Peixoto; Maurício T Nascimento; Rúbia Costa; Juliana Silva; Gaby Renard; Luiz Henrique Guimarães; Gerson Penna; Manoel Barral-Netto; Lucas P Carvalho; Paulo R L Machado; Edgar M Carvalho
Journal:  J Immunol Res       Date:  2020-08-06       Impact factor: 4.818

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.